Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Circ Cardiovasc Genet. 2012 Apr 1;5(2):153–155. doi: 10.1161/CIRCGENETICS.112.962910

Table 1.

Effect of PON1 Q192R on Cardiovascular Events in Clopidogrel-Treated Patients

Study Primary Outcome Number of Clopidogrel-
Treated Participants		 Effect of PON1
Q192R on CV
Endpoint
Bouman et al4 Stent thrombosis 41 cases, 71 controls Yes
Sibbing et al5 Stent thrombosis 127 cases, 1439 controls No
Trenk et al7 Composite CV endpoint 24 events, 760 patients No
Stent thrombosis* 18 events, 760 patients No
Lewis et al6 Composite CV endpoint 27 events, 227 patients No
Simon et al8 Composite CV endpoint 296 events, 2210 patients No
Composite CV endpoint 35 events, 371 patients No
Hulot et al9 Stent thrombosis 18 events, 371 patients No
Delaney et al12 Composite CV endpoint 225 cases, 468 controls† No
Paré et al17 Composite CV endpoint 227 events, 2534 patients No
Composite CV endpoint 114 events, 570 patients No

Abbreviations: CV, cardiovascular; PON1, paraoxonase 1

*

Cases were included that met ARC criteria for definite, possible, or probable stent thrombosis

†

Cases and controls were identified by algorithm using an electronic medical record-linked DNA repository